11 results about "Entacapone" patented technology

The invention discloses a multi-system drug release system for Parkinson's disease treatment, which is a capsule prepared from the following drug release systems and auxiliary materials in percentage by weight: 58.0 to 64.1 percent of an entacapone drug release system, 28.5 to 31.5 percent of a levodopa drug release system, 7.6 to 8.4 percent of a carbidopa drug release system and 0.5 to 1.5 percent of talcum powder, the drug-loaded pellet of the entacapone drug release system comprises a first pellet core, an isolation layer and an enteric layer which are sequentially arranged from inside to outside, and the drug-loaded pellet of the levodopa drug release system comprises a second pellet core and a first modification layer which are sequentially arranged from inside to outside, the drug-loaded pellet of the carbidopa drug release system comprises a third pellet core and a second modification layer which are sequentially arranged from inside to outside. The multi-system drug release system can realize independent and long-term slow release of three different active components without mutual interference. According to the method, a multi-system drug release system can be prepared with high loading capacity, and the problem of large dosage of drugs is effectively solved.

The present disclosure provides a method for the treatment of Parkinson's disease comprising simultaneously or sequentially administering to a patient in need of treatment of Parkinson's disease a dosage form comprising(i) levodopa in an amount ranging from 50 mg to 300 mg,(ii) carbidopa in an amount ranging from 25 mg to 150 mg or a therapeutically equivalent amount of another aromatic amino acid decarboxylase inhibitor, and(iii) entacapone in an amount ranging from 50 mg to 300 mg, wherein the proportion of entacapone to carbidopa in said dosage form ranges from 0.3:1.0 to 3.2:1.0 by weight, a moderately potent COMT inhibitor in an amount ranging from 25 mg to 200 mg, wherein the proportion of said COMT inhibitor to carbidopa in said dosage form ranges from 0.16:1.0 to 3.08:1.0 by weight, or a highly potent COMT inhibitor in an amount ranging from 1 mg to 100 mg, wherein the proportion of said COMT inhibitor to carbidopa in said dosage form ranges from 0.006:1.0 to 1.54:1.0 by weight. Pharmaceutical dosage form used in said method are also disclosed.

The present invention provides the use of entacapone, an entacapone derivative, or a stereoisomer, hydrate, or pharmaceutically acceptable salt thereof, in a human in need thereof for treating an injury or promoting wound healing or tissue regeneration.

Provided herein is a method for treating or preventing a disease or disorder associated with a deregulated NRF2 / KEAP1 pathway, comprising administering a subject in need thereof a therapeutically effective amount of entacapone or nitecapone or a pharmaceutically acceptable salt thereof; and entacapone or nitecapone can reversibly bind to KEAP1, those compounds activated NRF2 in vitro and in vivo by reversibly modifying C151 on KEAP1, and both drugs can enhance the expression of growth differentiation factor 15 (GDF15) and NRF2 downstream antioxidant response elements (ARE) genes.

The invention relates to an application of an FTO inhibitor in preparation of a medicine for inhibiting acute gout. The FTO inhibitor comprises meclofenamic acid sodium (MA), entacapone or FB23-2 and pharmaceutically acceptable salts of the meclofenamic acid sodium (MA), the entacapone or the FB23-2. An acute gout model mouse is intervened by using an FTO inhibitor, in the embodiment of the invention, the swelling degree of the sole of the mouse in an MA treatment group is reduced from 1.42 + / -0.11 to 1.25 + / -0.04, the lowest point of a pain region is increased from 0.47 + / -0.11 to 0.87 + / -0.13 after 6 hours, and the protein level of IL-1beta is reduced from 18.03 + / -4.95 to 4.34 + / -1.12; the swelling degree of the soles of the mice in the FB23-2 treatment group is reduced from 1.42 + / -0.11 to 1.22 + / -0.05, the lowest point of the pain region is increased from 0.47 + / -0.11 to 0.91 + / -0.15 after 6 hours, and the protein level of IL-1beta is reduced from 9.18 + / -1.62 to 3.83 + / -0.83; the results show that the FTO inhibitor can significantly reduce the swelling degree of mouse soles, significantly increase the pain area level and significantly reduce the IL-1beta protein expression level, so that the effect of treating acute gout is achieved, and the FTO inhibitor has important significance in developing novel drugs for treating acute gout.

Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.

The application belongs to the technical field of medicine, and specifically provides an entero-soluble ibrexin tablet with high bioavailability and a preparation method thereof. The entero-soluble tablet comprises a tablet core and an enteric coating, wherein the tablet core comprises an ibrexin coating compound, microcrystalline cellulose and magnesium stearate, and the ibrexin coating compound comprises ibrexin or a pharmaceutically acceptable salt thereof, an acid regulator, povidone and cross-linked sodium carboxymethyl cellulose. The ibrexin entero-soluble tablet of the application can make the drug reach the end of the small intestine or the colon for release, thereby avoiding the metabolism of cytochrome P450 (CYP) 3A, and at the same time, the acid regulator can locally provide an acidic environment for the active ingredient, so that the ibrexin is rapidly dissolved and released, and the side effects such as vomiting in the gastrointestinal tract are reduced.

The application discloses a detection method and application of entacapone double-dopa tablets, and operation steps of the detection method include sample pretreatment, chromatographic separation detection and quantification; the sample pretreatment comprises the following operation steps: grinding the entacapone double-dopa tablets into uniform fine powder, precisely taking a proper amount of tablet powder, adding a diluent to dissolve and stabilize, performing ultrasonic treatment, then constant volume and filtration, and taking the filtrate as a test sample solution; a solvent in the diluent is a mixed solution of methanol and water, and solutes in the diluent include sodium metabisulfite and disodium ethylenediaminetetraacetate. The application can realize synchronous analysis of entacapone, levodopa and carbidopa with rapidness, high separation degree, high sensitivity and high stability, so as to meet strict quality control requirements of the compound preparation.

The present invention provides a method for treatment of a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of a composition comprising carbidopa and levopoda, or pharmaceutically acceptable salts thereof, and concomitant oral administration of a catechol-O-methyl transferase (COMT) inhibitor, e.g., entacapone or tolcapone.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses an entacapone and didopa compound tablet and a preparation method thereof. The entacapone and didopa compound tablet is prepared from the following raw materials in parts by mass: 200 parts of entacapone, 90 to 110 parts of levodopa, 22 to 28 parts of carbidopa, 110 to 130 parts of mannitol, 150 to 170 parts of disintegrating diluent, 25 to 30 parts of disintegrating agent, 0.5 to 1.5 parts of stabilizer and 13 to 17 parts of lubricant. The stabilizer comprises citric acid and succinic acid. The specific stabilizer can adjust the pH value of the microenvironment so as to stabilize the main drug, enhance the antioxidant effect of the main drug and improve the disintegration performance at the same time. By screening and designing the raw materials, the entacapone and didopa compound tablet is similar to an original product in dissolution rate, equivalent to an original product in bioequivalence, good in friability, not easy to stick and excellent in stability.

The present invention pertains to: a maturation promoter for stem cell-derived non-mature nerve cells, the maturation promoter being characterized by containing at least one compound selected from the group consisting of asenapine and a salt, solvate, or derivative thereof, and entacapone and a salt, solvate, or derivative thereof; and a method for promoting maturation of stem cell-derived non-mature nerve cells, the method being characterized by making stem cell-derived non-mature nerve cells coexist with the maturation promoter.